Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $180
Goldman Sachs analyst Paul Choi maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and maintains the target price at $180.According to TipRanks data, the analyst has a success rate of 55.1%
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $175
BofA Securities analyst Tazeen Ahmad maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and maintains the target price at $175.According to TipRanks data, the analyst has a success rate of 50
Ascendis Pharma Says FDA Granted Orphan Drug Exclusivity To YORVIPATH For Treatment Of Hypoparathyroidism In Adults
Citi Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $178
Citi analyst David Lebovitz maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and maintains the target price at $178.According to TipRanks data, the analyst has a success rate of 54.2% and
Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald
Express News | Ascendis Pharma A/S : Evercore ISI Cuts Target Price to $191 From $200